(Alliance News) - Stock prices in London were mixed at midday on Friday, with the FTSE 100 edging higher as gains for telecommunications and pharmaceutical stocks offset a sharp fall for NatWest, while European markets diverged despite stronger-than-expected eurozone economic growth. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Friday. Read More
(Alliance News) - AstraZeneca PLC on Friday delivered strong third quarter results with sales ahead of forecast and lower than expected costs driving an even more impressive profit beat. Read More
(Alliance News) - Stock prices in London opened mixed on Friday, with the FTSE 100 rising as gains for AstraZeneca and BT Group offset losses for NatWest and Airtel Africa, while investors digested a contraction in the French economy. Read More
(Alliance News) - AstraZeneca, BP and NatWest report higher third-quarter pretax profits on Friday, while UK house price growth slows to its weakest pace since January 2024, according to figures from Nationwide. Read More
AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Says Enhertu, developed with Daiichi Sankyo Co Ltd, has been approved in the EU to treat adults with HER2-positive early breast cancer who have residual invasive disease following treatment before surgery. AstraZeneca says the European Commission approval follows results from the DESTINY-Breast05 phase III trial, presented in 2025, which showed Enhertu reduced the risk of invasive disease recurrence or death by 53% compared with T-DM1. Following approval, AstraZeneca will pay Daiichi Sankyo USD75 million as a milestone payment. Read More
(Alliance News) - AstraZeneca PLC on Saturday and Sunday reported a series of positive clinical trial results for ongoing clinical trials at the European Society for Medical Oncology Congress 2026 in Madrid. Read More
(Alliance News) - Computacenter raises its full-year profit outlook after strong third-quarter trading, while Plus500 forecast annual revenue and earnings ahead of market expectations. GSK has reported positive clinical trial results for two cancer treatments. Read More
(Alliance News) - Daiichi Sankyo Co Ltd on Friday said its cancer treatment Enhertu has received regulatory approval in China, while the company announced "promising" trial results. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Friday. Read More
(Alliance News) - AstraZeneca PLC on Thursday said subsidiary Alexion Pharmaceutical's Ultomiris has received accelerated approval in the US for the treatment of a rare kidney disease called immunoglobulin A nephropathy. Read More
AstraZeneca PLC - Cambridge, England-based pharmaceutical company - Says its Ultomiris drug has received accelerated approval from the US Food & Drug Administration to reduce proteinuria, or excess protein in urine, in adults with primary immunoglobulin A nephropathy, a rare inflammatory kidney disease, who are at risk of disease progression. Ultomiris becomes the first and only C5 complement inhibitor approved in the US for this indication. Approval follows interim results from the phase III I CAN trial, which showed a 43.4% reduction in proteinuria compared with placebo after 34 weeks. AstraZeneca says the trial remains ongoing to assess whether Ultomiris can slow kidney function decline, with continued approval potentially dependent on confirmation of clinical benefit. The approval marks the fifth indication for Ultomiris. Read More
(Alliance News) - Amgen Inc and AstraZeneca PLC on Tuesday hailed phase 3 trial results regarding their monoclonal antibody Tezspire, also known as tezepelumab. Read More
(Alliance News) - AstraZeneca PLC and Oracle Corp on Tuesday announced a global collaboration to use artificial intelligence to improve clinical trials, patient diagnosis and treatment. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Tuesday. Read More
(Alliance News) - The FTSE 100 made further strong gains on Friday as Bank of England Governor Andrew Bailey played down inflation fears, although banks missed out amid fears of a tax hit. Read More
(Alliance News) - The UK government has sought to persuade UBS Group AG to relocate its headquarters and stock market listing to London, as the Swiss banking giant considers its options amid tougher capital requirements in Switzerland, the Financial Times reported on Friday. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Friday. Read More
(Alliance News) - AstraZeneca PLC on Thursday announced its entry into a strategic drug discovery collaboration and licensing agreement with insitro. Read More